Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn:
“I look forward to presenting in a podium talk the updated results from our KOMET 007 phase 1/2 study combining the novel oral menin inhibitor ziftomenib with intensive chemotherapy 7+3 in fit patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements at the European Society of Hematology meeting ESH2026 in Stockholm.
The early results from this study have led to the ongoing registrational-intent and global randomized phase 3 study KOMET 017 of the same combination which I am honored to be the steering committee chair and where at Yale University we were the first center to open and to enroll the first patient globally.”
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients